Role of anticoagulation in non-ST-elevation myocardial infarction: a contemporary narrative review.
Paul Jie Wen TernKhung Keong YeoJack Wei Chieh TanChee Tang ChinRu San TanJonathan YapPublished in: Expert review of cardiovascular therapy (2024)
Patients presenting with non-ST-elevation myocardial infarction (NSTEMI) should be initiated on anticoagulation (e.g. heparin/low molecular weight heparin) for the initial hospitalization period for those medically managed or until percutaneous coronary intervention. Longer term management of NSTEMI for patients with an existing indication for long-term anticoagulation should comprise triple antithrombotic therapy of anticoagulant (preferably DOAC) with aspirin and clopidogrel for up to 1 month (typically 1 week or until hospital discharge), followed by DOAC plus clopidogrel for up to 1 year, and then DOAC monotherapy thereafter.
Keyphrases
- percutaneous coronary intervention
- st elevation myocardial infarction
- direct oral anticoagulants
- atrial fibrillation
- venous thromboembolism
- antiplatelet therapy
- st segment elevation myocardial infarction
- acute coronary syndrome
- acute myocardial infarction
- coronary artery bypass grafting
- coronary artery disease
- coronary artery bypass
- low dose
- heart failure
- growth factor
- preterm infants
- cardiovascular events
- combination therapy
- randomized controlled trial
- type diabetes
- open label
- left ventricular
- mesenchymal stem cells
- replacement therapy
- smoking cessation